P/E của cổ phiếu BMY là bao nhiêu?

BRISTOL-MYERS SQUIBB COMPANY (BMY) hiện giao dịch ở mức P/E 14.37 lần.

ROE của cổ phiếu BMY là bao nhiêu?

BRISTOL-MYERS SQUIBB COMPANY có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) 41.59%.

Tỷ suất cổ tức của BMY là bao nhiêu?

BRISTOL-MYERS SQUIBB COMPANY có tỷ suất cổ tức 3.87%.

Điểm chất lượng (Quality Score) của BMY là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của BMY ở mức 62/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu BMY không?

Điểm AI Timing của BMY là 91/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu BMY thuộc ngành nào?

BRISTOL-MYERS SQUIBB COMPANY được xếp vào ngành Healthcare >> Drug Manufacturers - General trên sàn NYSE

Cổ phiếu BMY (NYSE) | BRISTOL-MYERS SQUIBB COMPANY

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-06-30)

BMY AI Analysis Summary

Our AI summary for BMY: BRISTOL-MYERS SQUIBB COMPANY (NYSE), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 14.37, ROE of 41.59%, a dividend yield of 3.87%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

BMY

BRISTOL-MYERS SQUIBB COMPANY

USD 65.31

0.45 (0.69%) Day Change

Watchlist Portfolio Compare Chart

14.37

P/E

1.93

D/E

41.6%

ROE

10.6%

ROA

3.87%

Div Yield

-0.12

PEG

BRISTOL-MYERS SQUIBB COMPANY
TYPE: STOCK
MARKET: NYSE

Compare Watchlist Myport

USD 65.31 Price 0.45 (0.69%) Day Change	NEWS SCORE: 90

BMY Chất lượng tổng thể của cố phiếu Khá ( Chất lượng = 62) và Thời điểm mua ...(Sign In to See)...

Loading chart...

62 QUALITY

Signal: NEUTRAL

Signal Description: Company financial health is OK

Reason: [-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt lắm , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Tốt , ...

Yếu tố Chất lượng

50%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	90
Magic Formula Rank by ROA	718
Magic Formula Rank by ROE	718
Magic Formula Rank by ROIC	728
Price	65.31
PBV / Sector	5.98 / 2.68
Earning Per Share	4.55

PE / Sector	14.37 / 27.65
PEG or PE/Growth / Sector	-0.12 / 0.28
Average 1M Daily Value	563.28 M
Average 1W Daily Value	637.38 M

Yếu tố Kỹ thuật

85%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

47%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

70%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	18.87 / 17.30 GOOD
NPM Average (%) / Sector	9.30 / 17.60
NPM Change Average (%) / Sector	-80.97 / 92.67
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	10.59 / 8.73
ROA Average (%) / Sector	4.75 / 8.56
ROA Change Average (%) / Sector	-82.85 / 94.23
ROE (%) / Sector	41.59 / 26.78 GREAT
ROE Average (%) / Sector	14.53 / 13.05
ROE Change Average (%) / Sector	-106.95 / 96.64
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

83%

Dividend (%) / Sector	3.87 / 2.40 GOOD
Dividend Average (%) / Sector	4.29 / 3.39 GOOD
Dividend Change Average (%) / Sector	5.06 / 4.92

Chi tiết đăng ký

Analyze Date	2026-08-01 07:59:34
Symbol	BMY
Name	BRISTOL-MYERS SQUIBB COMPANY
Sector	Healthcare >> Drug Manufacturers - General
Market	NYSE
Listed Shares	2,042.07 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	133,367.67 / 256,404.20

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Route 206 & Province Line Road, Princeton, NJ, United States, 08543

Phone: 609 252 4621

Website: https://www.bms.com

Employees: 32,500

Sector: Healthcare >> Drug Manufacturers - General

Description: Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.